Dry age related macular degeneration

This early-stage study tests a new treatment called C.001 for people with retinal diseases that cause vision loss, such as geographic atrophy and Stargardt disease. The treatment is given as a single injection into the eye. The main goal is to check if it is safe, and researchers…

This phase 3 trial tests two injectable drugs, pozelimab and cemdisiran, alone or together, to slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes central vision loss. About 975 participants will receive either the drugs or a…

This study tests a device called PRIMA, which is implanted under the retina to help people with inherited retinal diseases like Stargardt disease and retinitis pigmentosa see better. The trial will enroll 5 adults with severe central vision loss and measure improvements in visual…

This study tests whether GAL-101 eye drops can slow the growth of geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. About 110 adults aged 55 and older with early-stage atrophy will use the drops or a placebo daily for up to two years…

This study tests a cell therapy called OpRegen for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. About 60 participants will receive a one-time injection of retinal cells under the retina during eye surgery. The m…

This study tests a device that delivers tiny electrical pulses through the eyelid to the back of the eye. The goal is to see if it can safely slow vision loss or improve sight in people with intermediate to advanced dry age-related macular degeneration. One hundred participants w…

This early-stage trial tests whether transplanting lab-grown retinal cells into the eye is safe for people with geographic atrophy from dry age-related macular degeneration. Twenty participants aged 55 and older will receive a transplant of their own reprogrammed cells into one e…

This study tests a new gene therapy (VV-14295) given as an injection into the eye for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The goal is to see if it is safe and can slow the growth of these blind spots. Ab…

This early-stage study tests an experimental drug called pozelimab, given as an injection into the eye, for people with geographic atrophy (GA) — a condition where parts of the retina stop working, leading to vision loss. The main goal is to check the drug's safety and tolerabili…

This study tests an experimental drug called ADX-038 in 240 people with geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. The drug is given as a shot under the skin and is compared to a placebo to see if it can slow the loss of a key…

This study tests an experimental drug called ONL1204, given as an eye injection, to see if it can slow the growth of blind spots in people with geographic atrophy, an advanced form of dry age-related macular degeneration. About 324 adults aged 55 and older will receive either the…

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive eye injections of the study drug or an approved treatment (SYFOVRE…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier studies for geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. The goal is to check long-term safety, including side effects and eye …

This study tests a single injection into the eye of a new drug (SAR446597) for people with geographic atrophy, a progressive form of age-related macular degeneration that causes vision loss. About 104 participants aged 60 and older will be followed for 2 years, with an optional 3…

This study tests whether injecting a person's own bone marrow stem cells into or near the eye can help treat various retinal and optic nerve diseases, including age-related macular degeneration, retinitis pigmentosa, and glaucoma. Participants receive stem cell injections via dif…

This Phase IIb trial tests a retinal implant (CPCB-RPE1) in 24 people with advanced dry age-related macular degeneration (geographic atrophy). Participants are randomly assigned to receive the implant or a sham procedure. The study measures changes in retinal sensitivity and visu…

This study tests a new gene therapy called BS01 for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. The treatment uses a harmless virus to deliver a light-sensitive protein to the eye, aiming to restore or preserve vi…

This study tests whether taking krill oil capsules daily for 3 months can reduce drusen (fatty deposits) in the eyes of people with early or intermediate dry age-related macular degeneration (AMD). 24 adults will receive either krill oil or a placebo. The main goal is to see if t…

This study tests whether dapagliflozin, a drug used for diabetes, can slow the progression of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 70 adults aged 50 and older with this condition will take the drug for 12 month…

This early-stage trial tests whether transplanting lab-grown retinal cells (RPESC-RPE-4W) into the eye is safe for people with dry age-related macular degeneration (AMD), a leading cause of vision loss. About 18 adults over 55 will receive the transplant and be monitored for side…

This pilot study is testing whether injections of a substance made from umbilical cord blood (called CB-PRP) can slow the progression of dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. The study will enroll 36 people aged 65 and older wi…

This study tests whether injecting a special blood product from umbilical cords into the eye can slow vision loss in people with dry age-related macular degeneration (AMD). The trial will involve 36 participants aged 65 and older with bilateral dry AMD. One eye will receive the i…

This study evaluates PathFinder 1.0, a software that analyzes OCT images of the retina to detect macular abnormalities such as epiretinal membrane, dry age-related macular degeneration, and other retinal conditions. About 400 adults with and without macular issues will undergo st…

This study tests a new eye imaging device (VG200D OCT) that takes detailed pictures of the retina. It compares these images to standard dye-based images (FA/ICGA) to see if the new device works just as well. About 30 adults with retina problems will take part. The goal is to see …

This study tests a special camera that takes detailed images of the retina using many wavelengths of light. Researchers hope it can find early signs of eye diseases like age-related macular degeneration, diabetic retinopathy, and glaucoma. About 1,000 adults in Melbourne, Austral…

This study is testing whether an AI system called DeepMSI AI can detect biomarkers of dry age-related macular degeneration (AMD) as accurately as experienced eye doctors. About 1,000 adults over 40, including those with and without AMD, will have their retinas imaged with a speci…

This study looks at whether a visual rehabilitation program can ease anxiety and depression in people with advanced age-related macular degeneration (AMD). Twenty-two participants will attend five group sessions over 60 days, learning skills like coin recognition, using voice ass…

This study tests whether adding emotional regulation therapy (ERT) to standard low vision rehabilitation (LVR) helps people with inherited retinal diseases who feel anxious or distressed about their vision. About 180 participants will receive LVR, which includes free vision-enhan…

This study looks at whether disulfiram (Antabuse), a drug used for alcohol use disorder, can improve vision in people with retinal degeneration (like macular degeneration or retinitis pigmentosa). Researchers believe it may calm overactive cells in the retina. The study involves …

This study follows 500 people with geographic atrophy, an advanced form of age-related macular degeneration that causes permanent vision loss. Participants receive avacincaptad pegol (IZERVAY) as part of their routine care. Researchers will collect data on treatment patterns, sid…

This international study aims to collect genetic and health information from 1,500 people with rare inherited retinal diseases like retinitis pigmentosa. It has two parts: a registry to gather genetic and vision data, and a natural history study that follows participants over tim…

This study observes 75 adults aged 55 and older with geographic atrophy (a late stage of age-related macular degeneration) to see how the condition progresses over a short time. Researchers will measure changes in eye structure and function, and explore links to genetics and life…

This study is creating a large collection of health information and biological samples (like blood, saliva, and eye tissue) from people with and without retinal diseases. Researchers aim to use this database to better understand conditions like age-related macular degeneration an…

This study watches how vision changes over two years in 50 people aged 65-90 with geographic atrophy (a form of dry age-related macular degeneration) who are already taking the drug pegcetacoplan. Researchers will use a special vision test that maps light sensitivity near damaged…

This study uses a special camera called an adaptive optics scanning laser ophthalmoscope to take incredibly detailed pictures of the retina, the light-sensitive layer at the back of the eye. Researchers will compare images from healthy people and those with eye diseases like Star…

This study tests two advanced eye imaging techniques—central microperimetry and radial OCT—to see if they can more accurately measure the progression of geographic atrophy, a severe form of age-related macular degeneration that can lead to blindness. Researchers will follow 80 ad…

This study uses a special camera (adaptive optics) to take detailed pictures of the back of the eye in people with inherited retinal diseases. Researchers want to see how individual cells change over time and after treatments. About 200 participants aged 5 to 70 will be observed,…

This study enrolls 25 people with severe retinal diseases like retinitis pigmentosa and Stargardt disease to test new ways of measuring visual function. Researchers will evaluate how well participants can perform various vision tests, such as navigating obstacles or detecting lig…

This study gathers eye scan images from 180 people with healthy eyes or eye diseases like glaucoma and retinal disease. The goal is to collect data using a new optical coherence tomography (OCT) device called A10900. No treatment or medication is given. The information will help …

This study aims to understand the natural bacteria living on the surface of the eye in both healthy people and those with certain eye conditions. Researchers will collect eye swabs from 500 adults in middle Tennessee to build a database of what a normal eye microbiome looks like.…

This study looks at how color vision changes over time in people with inherited retinal diseases (IRDs). Researchers will study 200 participants, including those with IRDs and healthy volunteers, to see how color vision loss relates to changes in the retina's structure. They are …